Status:
COMPLETED
An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neu
Lead Sponsor:
Cancer Research Network
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
The purpose of this study is to observe clinical outcomes of metastatic breast cancer patients whose tumors overexpress the Her2neu protein and are being treated with trastuzumab (Herceptin)either alo...
Detailed Description
In clinical practice, patients with metastatic breast cancer are being treated either with trastuzumab alone or trastuzumab in combination with chemotherapy or hormonal therapy as it has shown to incr...
Eligibility Criteria
Inclusion
- patients must have metastatic breast cancer
- tumor must have been determined to be Her-2 positive 3+ by immunohistochemistry or gene-amplified by fluorescence-in-situ hybridization (FISH)
- must have received trastuzumab alone or in combination with chemotherapy or hormonal therapy
- must not have received trastuzumab in the adjuvant or neoadjuvant setting
- must have started trastuzumab treatment for metastatic disease any time between January 1996 to June 2003
Exclusion
- patients who received trastuzumab prior to 1996
Key Trial Info
Start Date :
June 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT00153218
Start Date
June 1 2004
Last Update
February 14 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Research Network, Inc.
Plantation, Florida, United States, 33324
2
University of Pittsburgh Cancer Institute Magee-Womans Hospital
Pittsburgh, Pennsylvania, United States, 15213